|
 |
| Ex Vivo Metrics™: How Drug Studies in Reanimated Human Organs Could Revitalize the Drug Development Process
An editorial by Gerald Curtis, PhD
Fallout from the catastrophic phase I clinical trial of TeGenero’s monoclonal antibody TGN1412 in March 2006,1 in which 6 volunteers suffered life-threatening “cytokine storms,” includes newly tightened regulations in the United Kingdom and renewed concern worldwide about first-in-human trials, particularly for compounds with novel targets or mechanisms of action.
Read
more - More
Editorials
|
 |
| DNA
Genotyping from human FFPE Samples |
|
In this feasibility study, Applied Biosystems demonstrates how the combined
use Recover All Total Nucleic |
|
Acid Isolation Kit and TaqMan SNP Genotyping
Assay can result in high quality, reproducible, and reliable genotyping
data.. Read
more |
|
 |
Millipore has
launched the CellCiphr Cytotoxicity Profiling Assay Kit
using human HepG2 cells. This assay panel detects
drug-induced hepatotoxicity and is expected to be used
early in the drug discovery process. read
more
Cartesian Gridspeed, Ltd. announced the
opening of its new sales, marketing and technical support
subsidiary, SLIM Search, Inc. in Mission Viejo,
California. SLIM
Search, Inc. is marketing
its SLIM Search genomic search tool to universities,
government research, and research and development
departments of biotechnology corporations and individual
contributors. read
more
The new Variant Reporter Software from Applied
Biosystems automates detection of variants and
streamlines data analysis process. The software uses
proprietary algorithms to identify genetic variations
based on standardized or user-defined parameters. Results
are presented for validation in a visual format that
allows researchers to simultaneously compare multiple
quality control metrics. More information and a free trial
version are available at:
read
more
More
Products
|
 |
| We invite your comments and feedback for this edition of Biomarker Breakthroughs. Email us at
maloryea@gmail.com |
| |
|
|
March 21, 2007
STRATEGY
Covance Takes on Biomarkers
By Malorye Allison
Covance is one of the world’s largest contract research organizations, and so it’s new
Biomarker Services initiative illustrates two big trends– the need for biomarkers and the push to outsource research and development.
“There is a clear service gap in the industry related to biomarkers,” says Gordon
Kapke, senior director, Biomarker Services at Covance. The most obvious change is that Covance will be able to incorporate biomarkers into a much wider range of studies, even when the number of samples if relatively small. To make that possible, the company has made some strategic changes, added some tools to its “belt,” and adjusted its philosophy.
Read
more
TECHNOLOGY INSIGHT
By Malorye Allison
“It’s tremendously important not to waste a patient’s time with a treatment that’s not going to work,” says Walter
Darbonne, associate scientist at Genentech. Darbonne and his colleagues are looking for pharmacodynamic biomarkers in preclinical models, using tools including classic immunoassays, western blots, fluorescent-activated cell sorting, and gene expression.
Read
more
NEWS BRIEFS
CALENDER
Microarrays in
Medicine, April 11-13, Boston, MA
Optimizing Diagnostics and Therapeutics
Proteomic Sample
Preparation, April 11-12, Boston, MA
Optimizing Samples for Diagnostics and Drug Discovery
Genomic Sample
Preparation, April 12-13, Boston, MA
Optimizing Samples for Diagnostics and Drug Discovery
Tissue Technologies for Discovery
Research, April 11-13, Boston, MA
Fresh or Frozen — Optimizing Samples for Drug Discovery
Biomarker World
Congress, May 15-16, Philadelphia, PA
Dedicated to All Areas of Biomarker Research Spanning the Pharmaceutical and Diagnostic Pipeline
|
|
|
